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Methods: Blood samples were collected from patients with
rheumatoid arthritis (n=33) and healthy controls (n=33), serum
was harvested and stored at -20°C until testing. Aggrecan frag-
ments carrying the aggrecanase-derived neo-epitope NITEGE373
was determined using the G1-NITEGE373 ELISA, correspond-
ing fragments carrying the 374ARGSV neo-epitope using the
374ARGSV-G2 ELISA, and ﬁnally total aggrecan was determined
using the G1/G2 ELISA.
Results: We determined the concentration of G1-373NITEGE
aggrecan fragments in human serum and found 989 ng/ml ±
238 ng/ml (mean ± SD) and 310 ng/ml ± 42 ng/ml in patients
with RA and controls, respectively. This corresponds to a 3-fold
increase, which was highly signiﬁcant (p=0.004). In parallel, we
determined the concentration of the 374ARGSV-G2 fragments,
which also is derived from aggrecanase-cleavage of aggrecan,
however, no difference between RA and controls was detected.
Finally, circulating levels of total aggrecan, as determined by
the G1/G2 ELISA, was suppressed in RA patients vs controls
(p=0.0003), whereas MMP-derived fragments determined in the
342FFGVG-G2 ELISA was similar in the two groups.
Conclusions: We conclude, that whereas the total circulating
levels of aggrecan fragments carrying the G1 and/or G2 do-
mains is suppressed in RA patients, then the serum concentration
of the aggrecanase-derived aggrecan neo-epitopes, but not the
MMP-mediated, are elevated in in patients with RA. Circulating
aggrecanase-mediated aggrecan fragments may be more sensi-
tive than MMP-derived fragments to detect cartilage damage in
RA.
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Purpose: Serum measures of cartilage oligomeric matrix protein
(COMP), a marker of cartilage degradation, may be a promising
tool for evaluating OA severity or perhaps predicting disease
progression. Here we use COMP to predict the changes of early
knee OA detected by peripheral MRI during a two year follow up
study.
Methods: 33 patients (8 men and 25 women) aged 45-65 years
with chronic (>2 month duration) knee pain and diagnosed with
early knee osteoarthritis were chosen and followed for 24 months.
A blood sample was obtained at baseline and the serum concen-
tration of COMP was determined by immunoassay. MRI scans (3D
Gradient Echo for cartilage evaluation) for the symptomatic knee
were performed at baseline, 6 months, 12 months and 24 months
later. A trained radiologist semiquantitatively graded cartilage on a
scale of 0-4 in each of the medial tibia, lateral tibia, medial femur
and lateral femur. The maximum score that can be obtained is 24.
The baseline MRI cartilage score of all patients is ranged from 7
to 14.
Results: A signiﬁcant, positive regression was found between
baseline serum COMP concentration and the changes of MRI
cartilage scores over 24 months (R2=44.5%, P<0.001).
Conclusions: These results suggest that higher COMP at base-
line in patients with early OA could reﬂect increased cartilage
degeneration over time relative to those with lower COMP levels.
These ﬁndings support the hypothesis that a marker of cartilage
degradation may predict future cartilage degeneration.
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Purpose: Biomarkers to diagnose OA in an early stage and/or
to predict its course would be of great value. Therefore, we se-
lected a broad spectrum of commercially available serum and
urinary biomarkers representative of cartilage, bone and syn-
ovium metabolism for evaluation in the Cohort Hip & Cohort Knee
(CHECK). This cohort consists of 1002 participants with pain
and/or stiffness of knee and/or hip, aged 45-65 yrs, and who had
never or no longer than 6 months before visited their physician
for these symptoms for the ﬁrst time. Hip and knee radiographs
as well as clinical parameters and multiple questionnaires are
evaluated at regular intervals. Furthermore, blood (plasma and
serum; s) and urine (u) samples (multiple aliquots of all three)
are collected at 0, 2, 5, 8, and 10 yrs. Samples are obtained in
10 medical centers and processed in the same central laboratory,
all according to strict protocols. Biomarker measurement in these
samples provides a unique opportunity to study the diagnostic
and prognostic properties of biomarkers in early-stage OA. Base-
line biomarker measurement has recently been completed. The
data set is huge, speciﬁcally in combination with all patient char-
acteristics and longitudinal radiographic and clinical data. Before
relations are calculated we have to be sure about the quality of
the biomarker data set. This abstract covers this issue.
Methods: Baseline samples were thawed for the ﬁrst time.
Commercially available ELISA assays were performed to mea-
sure uCTX-II, uCTX-I (ImmunoDiagnostic Systems Ltd.), uNTX-I
(Wampole Laboratories), sCOMP (Anamar Med AB), sOC (IDS),
sHA (Corgenix Inc.), sPIIANP (Millipore Corp.), sCS846, and
sC1,2C (IBEX) and RIA assays for sPINP and sPIIINP (Orion
Diagnostica). All kits were purchased without commercial involve-
ment and for each biomarker kits were from the same badge.
A serum and urine pool were created from several OA patients and
aliquoted. At each of the assay days an aliquot was thawed and
included at multiple places in the assay plates. Each biomarker
was measured in all samples by the same technician in 8 days in
a period of 6 wks using 14 kits.
Results: Quality control as was performed by using a randomly
distributed pool sample, controls as supplied by manufacturers,
and blank samples in-between patient samples was unremarkable,
except for the COMP assay. The COMP assay’s pool sample
showed a remarkably variable biomarker concentration within and
between assay plates.
